These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 24246351)
1. Surgical utility of Afirma: effects of high cancer prevalence and oncocytic cell types in patients with indeterminate thyroid cytology. Harrell RM; Bimston DN Endocr Pract; 2014 Apr; 20(4):364-9. PubMed ID: 24246351 [TBL] [Abstract][Full Text] [Related]
2. Performance of the Afirma genomic sequencing classifier versus gene expression classifier: An institutional experience. Wei S; Veloski C; Sharda P; Ehya H Cancer Cytopathol; 2019 Nov; 127(11):720-724. PubMed ID: 31536167 [TBL] [Abstract][Full Text] [Related]
3. Performance of Afirma Gene Sequencing Classifier versus Gene Expression Classifier in thyroid nodules with indeterminate cytology. Yang Z; Zhang T; Layfield L; Esebua M J Am Soc Cytopathol; 2022; 11(2):74-78. PubMed ID: 34366280 [TBL] [Abstract][Full Text] [Related]
4. Impact of Afirma gene expression classifier on cytopathology diagnosis and rate of thyroidectomy. Sacks WL; Bose S; Zumsteg ZS; Wong R; Shiao SL; Braunstein GD; Ho AS Cancer Cytopathol; 2016 Oct; 124(10):722-728. PubMed ID: 27347838 [TBL] [Abstract][Full Text] [Related]
5. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules. McIver B; Castro MR; Morris JC; Bernet V; Smallridge R; Henry M; Kosok L; Reddi H J Clin Endocrinol Metab; 2014 Nov; 99(11):4069-77. PubMed ID: 24780044 [TBL] [Abstract][Full Text] [Related]
6. STATISTICAL COMPARISON OF AFIRMA GSC AND AFIRMA GEC OUTCOMES IN A COMMUNITY ENDOCRINE SURGICAL PRACTICE: EARLY FINDINGS. Harrell RM; Eyerly-Webb SA; Golding AC; Edwards CM; Bimston DN Endocr Pract; 2019 Feb; 25(2):161-164. PubMed ID: 30383497 [TBL] [Abstract][Full Text] [Related]
7. Has Afirma gene expression classifier testing refined the indeterminate thyroid category in cytology? Yang SE; Sullivan PS; Zhang J; Govind R; Levin MR; Rao JY; Moatamed NA Cancer Cytopathol; 2016 Feb; 124(2):100-9. PubMed ID: 26422098 [TBL] [Abstract][Full Text] [Related]
8. The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier. Hang JF; Westra WH; Cooper DS; Ali SZ Cancer Cytopathol; 2017 Sep; 125(9):683-691. PubMed ID: 28544601 [TBL] [Abstract][Full Text] [Related]
9. Comparison of Afirma Gene Expression Classifier with Gene Sequencing Classifier in indeterminate thyroid nodules: A single-institutional experience. Geng Y; Aguilar-Jakthong JS; Moatamed NA Cytopathology; 2021 Mar; 32(2):187-191. PubMed ID: 33010060 [TBL] [Abstract][Full Text] [Related]
10. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules. Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940 [No Abstract] [Full Text] [Related]
12. Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier. Wong KS; Angell TE; Strickland KC; Alexander EK; Cibas ES; Krane JF; Barletta JA Thyroid; 2016 Jul; 26(7):911-5. PubMed ID: 27219469 [TBL] [Abstract][Full Text] [Related]
13. UTILITY OF AFIRMA GENE EXPRESSION CLASSIFIER FOR EVALUATION OF INDETERMINATE THYROID NODULES AND CORRELATION WITH ULTRASOUND RISK ASSESSMENT: SINGLE INSTITUTIONAL EXPERIENCE. Sultan R; Levy S; Sulanc E; Honasoge M; Rao SD Endocr Pract; 2020 May; 26(5):543-551. PubMed ID: 31968199 [No Abstract] [Full Text] [Related]
14. Wide Inter-institutional Variation in Performance of a Molecular Classifier for Indeterminate Thyroid Nodules. Marti JL; Avadhani V; Donatelli LA; Niyogi S; Wang B; Wong RJ; Shaha AR; Ghossein RA; Lin O; Morris LG; Ho AS Ann Surg Oncol; 2015 Nov; 22(12):3996-4001. PubMed ID: 25862581 [TBL] [Abstract][Full Text] [Related]
15. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes. Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275 [TBL] [Abstract][Full Text] [Related]
16. Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: An institutional experience. Zhang L; Smola B; Lew M; Pang J; Cantley R; Pantanowitz L; Heider A; Jing X Diagn Cytopathol; 2021 Aug; 49(8):921-927. PubMed ID: 34021740 [TBL] [Abstract][Full Text] [Related]
17. UTILITY OF ULTRASOUND VERSUS GENE EXPRESSION CLASSIFIER IN THYROID NODULES WITH ATYPIA OF UNDETERMINED SIGNIFICANCE. Villabona CV; Mohan V; Arce KM; Diacovo J; Aggarwal A; Betancourt J; Amer H; Jose T; DeSantis P; Cabral J Endocr Pract; 2016 Oct; 22(10):1199-1203. PubMed ID: 27409819 [TBL] [Abstract][Full Text] [Related]
18. Impact of the Afirma Gene Expression Classifier Result on the Surgical Management of Thyroid Nodules with Category III/IV Cytology and Its Correlation with Surgical Outcome. Chaudhary S; Hou Y; Shen R; Hooda S; Li Z Acta Cytol; 2016; 60(3):205-10. PubMed ID: 27344463 [TBL] [Abstract][Full Text] [Related]
19. Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing. Nishino M; Mateo R; Kilim H; Feldman A; Elliott A; Shen C; Hasselgren PO; Wang H; Hartzband P; Hennessey JV Thyroid; 2021 Aug; 31(8):1253-1263. PubMed ID: 33813868 [No Abstract] [Full Text] [Related]
20. Prevalence of cancer and the benign call rate of afirma gene classifier in Endo M; Sipos JA; Ringel MD; Porter K; Nagaraja HN; Phay JE; Shirley LA; Long C; Wright CL; Roll K; Nabhan FA Cancer Med; 2021 Feb; 10(3):1084-1090. PubMed ID: 33449450 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]